12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

MabThera rituximab regulatory update

The chimeric mAb against CD20 antigen is approved in the EU to treat NHL, chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL) and rheumatoid arthritis (RA). Biogen Idec and Roche's Genentech unit co-market rituximab as Rituxan in the U.S., while Roche markets it as...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >